NAMI Advocacy Actions

NAMI works with policymakers to advance priority issues and ensure that the voice of people affected by mental illness is considered in policymaking. Read NAMI’s recent letters to federal leaders, submitted comments and testimony and other resources.

NAMI is committed to ensuring accessibility for people with disabilities. If you would like to request an accessible version of any document on this page, please email us.

Filter By:
Statement on Medicaid
04/24/2023
Statement expressing opposition to upcoming congressional legislation that would add work requirements, to the Medicaid program, which would have a disastrous impact on program access.
Letter to Congressional Leadership on Medicaid
04/19/2023
Letter to Congressional leadership, urging protection of the Medicaid program from cuts or harmful changes in any budget negotiations or other legislative venue this year.
Letter to Congressional Committee Leadership on Research and Innovation & Criminal Justice
04/19/2023
Letter to House and Senate Appropriations Committee leadership requesting $35 million for the U.S. Centers for Disease Control and Prevention (CDC), $25 million for the National Institutes of Health and $1 million for the National Institute of Justice to conduct public health research into firearm morbidity and mortality prevention.
Statement on Medicaid
04/17/2023
Statement urging Congress to reject adding a ‘work requirement’ policy to the Medicaid program.
Statement on Medication Access
04/11/2023
Statement with patient advocacy organizations on the Alliance for Hippocratic Medicine et al v FDA et al ruling and implications for future access to FDA-approved drugs.
Congressional Testimony on Mental Health Funding
04/05/2023
Hannah Wesolowski's congressional testimony, on behalf of NAMI, to the Senate Labor-HHS-Education Appropriations Subcommittee on NAMI's FY 2024 appropriations priorities.
Letter to FDA Commissioner & HHS Secretary on Research and Treatment Innovation
04/04/2023
Letter to HHS Secretary Becerra and FDA Commissioner Califf urging the Federal Drug Administration FDA to reissue its ban of electrical stimulation devices used to treat self-injurious or aggressive behavior.
Letter to Congressional Committee Leadership on Mental Health Funding
04/01/2023
Letter to Chairwoman Murray detailing NAMI's appropriations requests for FY2024 and urging the continued support of mental health as a national priority.
Statement on Health Coverage
03/30/2023
Statement in response to the ruling in the Braidwood versus Becerra case, which threatens coverage of U.S. Preventive Services Task Force recommended preventive services without cost sharing as required under the Affordable Care Act.
Congressional Testimony on Mental Health Funding
03/23/2023
Hannah Wesoloski's Congressional testimony, on behalf of NAMI, to the House Labor-HHS-Education Appropriations Subcommittee on NAMI's FY 2024 appropriations priorities.
Displaying results 91-100 (of 336)
 <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >